Bloomberg Turnaround: AstraZeneca

Jul.03 -- For Pascal Soriot, less is more. He's shed development drugs he sees little chance of becoming viable, relentlessly focused on oncology and bio-pharmaceuticals to replenish the company's drugs pipeline while throwing AstraZeneca's doors open to encourage collaboration. Soriot takes us through his turnaround plan and the key to pushing through cultural change.